MIM
TPST icon

Monashee Investment Management’s Tempest Therapeutics TPST Stock Holding History

Monashee Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,615
Closed -$868K – 118
2021
Q3 		$868K Sell
4,615
-4,127
-47% -$803K 0.16% 121
2021
Q2 		$1.27M Buy
8,742
+6,178
+241% +$1.39M 0.15% 175
2021
Q1 		$600K Buy
+2,564
New +$1.04M 0.09% 210
2020
Q1 		– Sell
-719
Closed -$945K – 90
2019
Q4 		$945K Buy
+719
New +$1.01M 0.88% 41

Other funds holding TPST

RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Monashee Investment Management's TPST Position: Q4 2021 in Review

Monashee Investment Management sold out of Tempest Therapeutics (TPST) in Q4 2021, closing a stake of 4,615 shares — an estimated $868K sold.

Monashee Investment Management first reported a position in TPST in Q4 2019 and held it in 4 quarters. The position peaked at $1.27M in Q2 2021. 17 funds tracked by Wall St. Rank hold TPST as of Q4 2021.

  • Monashee Investment Management reported no remaining Tempest Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Monashee Investment Management sold 4,615 Tempest Therapeutics shares in Q4 2021, an estimated $868K.
  • Monashee Investment Management first reported a position in Tempest Therapeutics in Q4 2019 and held it in 4 quarters.
  • Monashee Investment Management's Tempest Therapeutics position peaked at $1.27M in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2021.

Based on Monashee Investment Management's 13F filing for Q4 2021, filed 7 Feb 2022.